Organogenesis Holdings

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Organogenesis Holdings reports Q4 revenue decline but exceeds guidance

Organogenesis Holdings faced revenue decline in Q4 2022 but exceeded guidance expectations.
Operational progress in clinical trials and a healthy cash position are notable strengths.
Challenges include declining product sales and increased operating expenses.
Strategic investments and growth opportunities in clinical initiatives are key focus areas for 2023.

Organogenesis Holdings reports robust Q1 revenue growth and strategic focus

Organogenesis Holdings delivered strong revenue growth driven by Advanced Wound Care products, while facing challenges with increased expenses and a net loss.
The company's focus on innovation, market expansion, and cost management presents opportunities for sustained growth and competitive positioning.
Navigating regulatory requirements and market dynamics will be crucial for Organogenesis to capitalize on opportunities and mitigate challenges in the upcoming quarters.

Organogenesis Holdings faces revenue challenges amidst strong business trends

Organogenesis Holdings faced revenue challenges due to LCDs impacting products, leading to withdrawn guidance. Despite this, the company maintained a strong gross profit margin and focused on strategic sales shifts. Opportunities for growth exist in product focus and ongoing trials.

Organogenesis reports Q3 revenue decline, eyes growth amid regulatory shifts

Organogenesis Holdings navigated challenges in Q3 2023 with a focus on operational efficiency, financial strength, and strategic growth initiatives for the future.
While facing revenue declines and market uncertainties, the company capitalized on positive regulatory developments and operational advancements to drive performance.
Looking ahead, Organogenesis aims to address challenges, seize growth opportunities, and maintain its competitive edge in the evolving healthcare market landscape.

Organogenesis Holdings reports Q4 revenue decline but anticipates 2024 growth

Organogenesis Holdings faced challenges in Q4 but showed positive momentum and progress in clinical trials. The company expects revenue growth in 2024 and is focusing on customer engagement and new product launches for further expansion.

Organogenesis Holdings beats revenue expectations, eyes FDA approval for ReNu

Organogenesis Holdings demonstrated solid financial performance in Q1, with revenue exceeding expectations and improved operating metrics.
While facing challenges in certain revenue segments, the company's focus on innovation and regulatory progress presents growth opportunities.
Maintaining a strong cash position and reaffirming revenue guidance underscore Organogenesis' resilience and strategic outlook for the future.

Organogenesis Holdings exceeds Q3 revenue guidance, focuses on innovation

Organogenesis Holdings delivered a strong performance in Q3 2024, surpassing revenue guidance and demonstrating solid financial results.
While facing challenges such as potential market disruption and regulatory issues, the company remains focused on strategic initiatives and innovation to drive growth.
With opportunities in Medicare reimbursement, product development, and regulatory milestones, Organogenesis is well-positioned for future success and revenue expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination

Organogenesis Commends Final LCDs

Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ross Osborne - Cantor Fitzgerald Ryan Zimmerman - BTIG Operator Please stand by. Welcome ladies and gentlemen to the Third Quarter of Fiscal Year 2024 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants are placed in listen-only mode.

Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript

Organogenesis (ORGO) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.02 per share a year ago.

Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates

Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases

Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA).

Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th.

Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Organogenesis (ORGO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Organogenesis (ORGO) Shows Fast-paced Momentum But Is Still a Bargain Stock

CANTON, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the publication of “Dehydrated Amnion Chorion Membrane Versus Standard of Care for Diabetic Foot Ulcers: A Randomised Controlled Trial” in the Journal of Wound Care.

Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers

CANTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the following upcoming investor conferences:

Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September

Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Brooks O'Neill - Lake Street Drew Ranieri - Morgan Stanley Matthew Park - Cantor Fitzgerald Operator Please stand by. Welcome ladies and gentlemen to the Second Quarter 2024 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants are placed in listen-only mode.

Organogenesis Holdings, Inc. (ORGO) Q2 2024 Earnings Call Transcript

Organogenesis (ORGO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.04 per share a year ago.

Organogenesis (ORGO) Reports Q2 Loss, Tops Revenue Estimates

CANTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced a development program update for ReNu®, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA).

Organogenesis Shares ReNu® Program Update

CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) --  Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that second quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, August 8th.

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024

CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the Truist Securities MedTech Conference, which is being held at the InterContinental Boston in Boston, MA on Tuesday, June 18th. Management will participate in 1x1 meetings. There will be no formal presentation.

Organogenesis Holdings Inc. to Participate in the Truist Securities MedTech Conference

Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q1 2024 Earnings Conference Call May 9, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Ross Osborn - Cantor Fitzgerald Drew Ranieri - Morgan Stanley Operator Welcome ladies and gentlemen to the First Quarter and Fiscal Year 2024 Earnings Conference Call for Organogenesis Holdings Inc. Please note, that this conference call is being recorded and the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks today may contain forward-looking statements that are based on current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including the risks and uncertainties described in the company's filings with the Securities and Exchange Commission, including Item 1A, Risk Factors, of the company's most recent annual report and a sequential filing with quarterly reports.

Organogenesis Holdings, Inc. (ORGO) Q1 2024 Earnings Call Transcript

CANTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that its Phase 3 randomized control trial evaluating the safety and efficacy of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA) achieved its primary endpoint upon the analysis of positive top line data.

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis

CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that first quarter of fiscal year 2024 financial results will be reported after the market closes on Thursday, May 9th.

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

CANTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ: ORGO) a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that on March 29, 2024, the United States District Court for the Eastern District of New York granted, with prejudice, the Company's motion to dismiss all claims asserted.

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results.

Why Organogenesis Holding Stock Plummeted by 18% Today

Organogenesis Holdings, Inc. (ORGO) Q4 2023 Earnings Call Transcript

Organogenesis (ORGO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.06 per share a year ago.

Organogenesis (ORGO) Reports Break-Even Earnings for Q4

CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2023.

Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference, which is being held at the Cliff Lodge in Snowbird, UT from February 13th-14th.

Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference

CANTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that fourth quarter and fiscal year 2023 financial results will be reported after the market closes on Thursday, February 29th.

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024

Does Organogenesis (ORGO) have what it takes to be a top stock pick for momentum investors? Let's find out.

News for Organogenesis Holdings Stock (ORGO)